[Combination chemotherapy with methotrexate (MTX), vincristine (VCR), cisplatinum (CDDP), cyclophosphamide (CPM), adriamycin (ADM), and bleomycin (BLM); MVP-CAB in patients with advanced urothelial tract cancer]

MeSH terms

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Bleomycin / administration & dosage
• Bleomycin / adverse effects
• Carcinoma, Squamous Cell / drug therapy
• Carcinoma, Squamous Cell / mortality
• Carcinoma, Transitional Cell / drug therapy
• Carcinoma, Transitional Cell / mortality
• Cisplatin / administration & dosage
• Cisplatin / adverse effects
• Cyclophosphamide / administration & dosage
• Cyclophosphamide / adverse effects
• Doxorubicin / administration & dosage
• Doxorubicin / adverse effects
• Female
• Humans
• Leukopenia / chemically induced
• Male
• Methotrexate / administration & dosage
• Methotrexate / adverse effects
• Middle Aged
• Remission Induction
• Urinary Bladder Neoplasms / drug therapy
• Urinary Bladder Neoplasms / mortality
• Urologic Neoplasms / drug therapy*
• Urologic Neoplasms / mortality
• Vincristine / administration & dosage
• Vincristine / adverse effects